Amongst a crowded research space, Skye Bioscience, Inc. aims to differentiate itself with a longer-term approach to combatting obesity.
Its lead asset, nimacimab, functions as a negative allosteric modulating antibody. It works through inhibiting the receptor CB1, which acts...